Alzheimers Disease And Dementia Conferences | Europe | Asia | Middle East | Canada | Japan | Australia | USA

Alzheimers Disease and Dementia

Alzheimer's disease is a neurodegenerative disorder that leads to the death of brain cells. It progresses over time and worsens at the end. Alzheimer's is the cause of 60-70% of dementia. Dementia is a neurological condition in which the ability to think and remember small things becomes so severe that is starting to affect their daily routine.

The most common symptoms of Alzheimer's and dementia are forgetting becomes very often, difficulty in remembering some events occurs, and in some severe cases, patients suffer difficulty in remembering recent events and conversations. Alzheimer's disease and dementia patients develop hindrances in making judgments, reasoning, thinking, decision and performing daily tasks.

The precise cause of Alzheimer's and dementia are not fully understood but most of the researchers think that it is a result of various factors: genetics, environmental, and lifestyle. The risk factors associated with Alzheimer's and dementia are age, syndrome, sex, trauma, lifestyle, social engagement, and family genetics.

As these diseases are progressive, not even a single cure proves to revert this process. Patients affected with this disease need help from others.

Sub-tracks:

Causes and Prevention of Alzheimer’s
Vascular Dementia
Alzheimer’s Disease Diagnosis and Symptoms
Recent Studies & Case Reports
Alzheimer prevention and risk factors
Alzheimer’s Clinical Trials and Studies
Managing Dementia

Market Analysis: The Alzheimer's Disease and Dementia market is set for strong growth between 2025 and 2030, with CAGRs ranging from 5.57% to 20%. This surge is driven by an aging population and advancements in diagnostics and therapies. The dementia treatment market is projected to exceed $28 billion by 2030, with Alzheimer's diagnostics growing at an 11.03% CAGR due to increased biomarker use. The Lewy Body Dementia treatment market is also expanding rapidly, with a 10.6% CAGR, supported by rising R&D, emerging therapies like lecanemab and donanemab, and improved early detection tools.

Tracks